Jennifer Janik

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy

Alyssa J. Porter, M. Zody, M. Lederman, 2014, PloS one.

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

R. Schooley, R. Lempicki, C. Rinaldo, 2010, The Journal of infectious diseases.

Safety , Tolerability , and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa-2 a in HIV-1 – Monoinfected Participants : A Phase II Clinical Trial

R. Schooley, R. Lempicki, C. Rinaldo, 2010 .

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

D. Clifford, N. Frahm, J. McElrath, 2016, Journal of acquired immune deficiency syndromes.

Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

V. Johnson, M. Saag, I. Frank, 2006, The Journal of infectious diseases.

Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers

K. Dooley, S. Dorman, J. Park, 2015, Antimicrobial Agents and Chemotherapy.